Magnetovacci nation as a novel method to assess and quantify dendritic cell tumor antigen capture and delivery to lymph nodes

Cancer Research

Volumn 69, Issue 7, 2009, Pages 3180-3187

  Long, Christopher M ^a,b   Van Laarhoven, Hanneke W M ^a,c   Bulte, Jeff W M ^a,b,e   Levitsky, Hyam I ^a,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d 217 Traylor Building ^*  (United States)

^e 217 Traylor Building   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; SUPERPARAMAGNETIC IRON OXIDE; TUMOR ANTIGEN; AMINOQUINOLINE DERIVATIVE; FERRIC ION; FERRIC OXIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMIQUIMOD; IMMUNOLOGICAL ADJUVANT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY COMBINING SITE; ANTIGEN DETECTION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNIZATION; CANCER MODEL; CELL LABELING; CELL MIGRATION; CELL TRANSFER; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; IN VIVO STUDY; LYMPH NODE; MAGNETOVACCINATION; MOUSE; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TUMOR CELL; VACCINATION; ANIMAL; ANTIGEN PRESENTATION; C57BL MOUSE; EXPERIMENTAL MELANOMA; IMAGE PROCESSING; IMMUNOLOGY; MAGNETISM; METABOLISM; METHODOLOGY;

ADJUVANTS, IMMUNOLOGIC; AMINOQUINOLINES; ANIMALS; ANTIGEN PRESENTATION; CANCER VACCINES; DENDRITIC CELLS; FEMALE; FERRIC COMPOUNDS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMAGE PROCESSING, COMPUTER-ASSISTED; LYMPH NODES; MAGNETIC RESONANCE IMAGING; MAGNETICS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL;

EID: 66149142268     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-3691     Document Type: Article

References (33)

1. Gattinoni L1 Powell DJ, Jr., Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer:building on success. Nat Rev Immunol 2006;6:383-393
2. Ribas A, Butterfield LH, Glaspy JA, Economou JS. Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol 2003;21:2415-2432
3. Ridgway D. The first 1000 dendritic cell vaccinées. Cancer Invest 2003;21:873-886
4. Rosenberg SA Yang JC, Restifo NP. Cancer immuno-therapy: moving beyond current vaccines. Nat Med 2004;10:909-915
5. Martln-Fontecha A, Sebastiani S, Hopken UE, et al. Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J Exp Med 2003;198:615-621
6. Kedl RM, Kappler JW, Marrack P. Epitope dominance competition and T cell affinity maturation. Curr Opin Immunol 2003;15:120-127.
7. Smith AL, Wikstrom ME, Fazekas de St Groth B. Visualizing T cell competition for peptide/MHC com- plexes: a specific mechanism to minimize the effect of precursor frequency. Immunity 2000;13:783-794
8. Bonifaz L1 Bonnyay D, Mahnte K, Rivera M1 Nussenzweig MC1 Steinman RM Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 In the steady state leads to antigen presentation, on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med 2002;196:1627-1638.
9. Hernandez J. Aung S, Redmond WL, Shennan LA. Phenotypic and functional analysis of CD8(+) T cells undergoing peripheral deletion, in response to cross- presentation of self-antigen. J Exp Med 2001;194:707-717
10. Kurts C, Kosaka H, Carbone FR, Miller JF, Heath WR. Class I-restricted cross-presentation of exogenous self- antigens leads to deletion, of autoreactive CD8(+) T cells. J Exp Med 1997:186:239-245
11. Adema GJ, de Vries IJ, Punt CJ, Figdor CG. Migration of dendritic cell based cancer vaccines: in vivo Veritas? Curr Opin Immunol 2005;17:170-174
12. Ahrens ET, Flores R1 Xu H1 Morel PA. In vivo imaging platform for tracking immunotherapeutic cells. Nat Blotechnol 2005;23:983-987
13. Baumjohann D, Hess A, Budinsky L, Brune K, Schuler G, Lutz MB. In vivo magnetic resonance imaging of dendritic cell migration into the draining lymph nodes of mice. Eur J Immunol 2006;36:2544-2555
14. Bulte JW, Kraitchman DL. Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomed 2004;17:484-499
15. de Vries IJ, Lesterhuis WJ, Barentsz JO, et al. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol 2005;23:1407-1413
16. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med 2004;10:475-480.
17. Huang AY, Bruce AT, Pardoll DM, Levitsky HI. in vivo cross-priming of MHC class I-restricted antigens requires the TAP transporter. Immunity 1996;4:349-355
18. Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC class [-restricted tumor antigens. Science 1994;264:961-5.
19. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sei U S A 1993;90:3539-3543
20. Itano AA McSorley SJ, Reinhardt RL, et al. Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell- mediated immunity. Immunity 2003;19:47-57.
21. Muranskl P, Boni A, Antony PA, et al. Tumor-specific Thl7-polarized cells eradicate large established mela- noma. Blood 2008;112:362-373
22. Levitsky HI, Lazenby A, Hayashi RJ, Pardoll DM. In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J Exp Med 1994;179:1215-1224
23. Walczak P, Kedzlorek DA, Gilad AA, Lin S, Bulte JW. Instant MR. labeling of stem, cells using magneto- electroporation. Magn Reson Med 2005;54:769-774
24. Bulte JW, Arbab AS, Douglas T, Frank JA. Preparation of magnetically labeled cells for cell tracking by magnetic resonance imaging. Methods Enzymol 2004; 386:275-299
25. Bulte JW Douglas T1 Witwer B1 et al. Magneto- dendrimers allow endosomal magnetic labeling and in vivo tracking of stem cells. Nat Biotechnol 200.1;19: 1141-1147.
26. Lu Z1 Yuan L1 Zhou X. Sotomayor E, Levitsky HI, Pardoll DM. CD40-independen.t pathways of T cell help for priming of CD8(t) cytotoxic T lymphocytes. J Exp Med 2000;191:541-550
27. Allan RS, Waithman J, Bedoui S, et al. Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming. Immunity 2006;25:153-162
28. NaIr S, McLaughlin C, Weizer A, et al. Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J Immunol 2003;171:6275-6282
29. Baumjohann D, Lutz MB. Non-invasive imaging of dendritic cell migration in vivo. Immunobiology 2006; 211:587-597
30. Blocklet D, Toungouz M, Kiss R, et al. 11 lln-oxine and 99mTc-HMPAO labelling of antigen-loaded dendritic cells: in vivo imaging and influence on motility and actin content Eur J Nud Med MoI Imaging 2003;30: 440-447
31. De Vries IJ, Krooshoop DJ, Scharenborg NM, et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is deter- mined by their maturation state. Cancer Res 2003:63: 12-17
32. Porgador A, Irvine KR, Iwasaki A, Barber BH, Restifo NP, Germain. RN. Predominant role for directly trans- fected dendritic cells in antigen presentation to CDS+ T cells after gene gun immunization. J Exp Med.1998;.188:1075-1082
33. Garg S, Oran A, Wajchman J, et al. Genetic tagging shows increased frequency and longevity of antigen-presenting skin-derived dendritic cells in vivo. Nat Immunol 2003;4:907-912